Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
According to the latest filings from the US Securities and Exchange Commission (SEC), biotechnology company Inovio Pharmaceuticals has officially suspended and terminated its at-the-market (ATM) equity offering prospectus previously established with investment bank Oppenheimer & Co.

According to the latest filings from the US Securities and Exchange Commission (SEC), biotechnology company Inovio Pharmaceuticals has officially suspended and terminated its at-the-market (ATM) equity offering prospectus previously established with investment bank Oppenheimer & Co.

老虎证券老虎证券2026/04/02 10:40
Show original
This decision means that Inovio Pharmaceuticals will temporarily be unable to flexibly issue new shares and raise funds in the open market through the ATM financing mechanism. The ATM issuance model typically allows listed companies to issue shares opportunistically based on market conditions as needed, serving as a flexible and efficient financing tool. The termination of this plan may reflect an adjustment in the company’s current financing strategy or considerations regarding the market environment. Market participants will closely monitor the potential impact of this move on the company’s future funding status and the progress of its research and development pipeline.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11

SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.

The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).

智通财经2026/09/22 07:11